Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry
Aliment Pharmacol Ther 2010; 32: 535–542 Summary Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2010-08, Vol.32 (4), p.535-542 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 542 |
|---|---|
| container_issue | 4 |
| container_start_page | 535 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 32 |
| creator | Alam, I. Stainbrook, T. Cecil, B. Kistler, K. D. |
| description | Aliment Pharmacol Ther 2010; 32: 535–542
Summary
Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily.
Aim To examine whether improved adherence was associated with RBP vs. RBV.
Methods Accurate Dosing in Hepatitis C: Examining the RibaPak Experience (ADHERE) was a U.S., multi‐centre, prospective registry capturing data on adherence with RBP vs. RBV in adults with HCV. Adherence was measured by the proportion of subjects remaining on treatment at weeks 4, 12 and 24; by pill counts; and by the proportion of subjects who took ≥80% of their prescribed dose.
Results A total of 503 patients (RBP = 346, RBV = 157) from 33 sites were included. A greater proportion of RBV vs. RBP subjects prematurely discontinued treatment. At 12 and 24 weeks, a greater proportion of RBP vs. RBV subjects took ≥80% of their prescribed doses (P |
| doi_str_mv | 10.1111/j.1365-2036.2010.04381.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_762265820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733597161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4301-8fa622e3e1bc66524ffd04db074a6667c944dab10267a290948d10b39b75e7b73</originalsourceid><addsrcrecordid>eNqNkVtP2zAUgC00BB3wFya_oD2lHF9iJ5N4qLpuRUICIeDVchKbusql2CmQfz9nLfC4-cE-tr9zfPkQwgSmJLaL9ZQwkSYUmJhSiKvAWUambwdo8rHxBU2AijyhGWHH6GsIawAQEugROqaQAkhGJ-h50a50W5oK62plvIkh7ju8nD_iPs71ZsCvrl_hlXuKU1x1wWDvCv3ivGux7XyzrXXvuvYHtq7VNdaxG4IJ2PquGWvg2c_l4m6BvXlyoffDKTq0ug7mbD-eoIdfi_v5Mrm--X01n10nJWdAksxqQalhhhSlECnl1lbAqwIk10IIWeacV7og8Y1S0xxynlUECpYXMjWykOwEfd_V3fjueWtCrxoXSlPXujXdNigZy4s0i1_1T5KxNJdEkEhmO7L0XQjeWLXxrtF-UATUaEat1ShAjQLUaEb9NaPeYuq3_SHbojHVR-K7igic7wEdSl1bH7W48MkxgJzwPHKXO-7V1Wb47wuo2e39GLE_chCohg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733597161</pqid></control><display><type>article</type><title>Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Alam, I. ; Stainbrook, T. ; Cecil, B. ; Kistler, K. D.</creator><creatorcontrib>Alam, I. ; Stainbrook, T. ; Cecil, B. ; Kistler, K. D.</creatorcontrib><description>Aliment Pharmacol Ther 2010; 32: 535–542
Summary
Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily.
Aim To examine whether improved adherence was associated with RBP vs. RBV.
Methods Accurate Dosing in Hepatitis C: Examining the RibaPak Experience (ADHERE) was a U.S., multi‐centre, prospective registry capturing data on adherence with RBP vs. RBV in adults with HCV. Adherence was measured by the proportion of subjects remaining on treatment at weeks 4, 12 and 24; by pill counts; and by the proportion of subjects who took ≥80% of their prescribed dose.
Results A total of 503 patients (RBP = 346, RBV = 157) from 33 sites were included. A greater proportion of RBV vs. RBP subjects prematurely discontinued treatment. At 12 and 24 weeks, a greater proportion of RBP vs. RBV subjects took ≥80% of their prescribed doses (P < 0.05). For patients who remained on treatment, the mean milligrams missed per day was significantly greater for RBV vs. RBP at 24 weeks.
Conclusions First line treatment with RBP may offer the best prospect for less discontinuation and improved treatment adherence.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2010.04381.x</identifier><identifier>PMID: 20500732</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Adult ; Antiviral Agents - administration & dosage ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Data processing ; Digestive system ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatitis C virus ; Humans ; Male ; Medical sciences ; Medication Adherence ; Middle Aged ; Pharmacology. Drug treatments ; Prospective Studies ; Registries ; Ribavirin ; Ribavirin - administration & dosage ; Ribavirin - therapeutic use ; Tablets</subject><ispartof>Alimentary pharmacology & therapeutics, 2010-08, Vol.32 (4), p.535-542</ispartof><rights>2010 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4301-8fa622e3e1bc66524ffd04db074a6667c944dab10267a290948d10b39b75e7b73</citedby><cites>FETCH-LOGICAL-c4301-8fa622e3e1bc66524ffd04db074a6667c944dab10267a290948d10b39b75e7b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2010.04381.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2010.04381.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27922,27923,45572,45573,46407,46831</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23009149$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20500732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alam, I.</creatorcontrib><creatorcontrib>Stainbrook, T.</creatorcontrib><creatorcontrib>Cecil, B.</creatorcontrib><creatorcontrib>Kistler, K. D.</creatorcontrib><title>Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Aliment Pharmacol Ther 2010; 32: 535–542
Summary
Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily.
Aim To examine whether improved adherence was associated with RBP vs. RBV.
Methods Accurate Dosing in Hepatitis C: Examining the RibaPak Experience (ADHERE) was a U.S., multi‐centre, prospective registry capturing data on adherence with RBP vs. RBV in adults with HCV. Adherence was measured by the proportion of subjects remaining on treatment at weeks 4, 12 and 24; by pill counts; and by the proportion of subjects who took ≥80% of their prescribed dose.
Results A total of 503 patients (RBP = 346, RBV = 157) from 33 sites were included. A greater proportion of RBV vs. RBP subjects prematurely discontinued treatment. At 12 and 24 weeks, a greater proportion of RBP vs. RBV subjects took ≥80% of their prescribed doses (P < 0.05). For patients who remained on treatment, the mean milligrams missed per day was significantly greater for RBV vs. RBP at 24 weeks.
Conclusions First line treatment with RBP may offer the best prospect for less discontinuation and improved treatment adherence.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Data processing</subject><subject>Digestive system</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C virus</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medication Adherence</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Ribavirin</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - therapeutic use</subject><subject>Tablets</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkVtP2zAUgC00BB3wFya_oD2lHF9iJ5N4qLpuRUICIeDVchKbusql2CmQfz9nLfC4-cE-tr9zfPkQwgSmJLaL9ZQwkSYUmJhSiKvAWUambwdo8rHxBU2AijyhGWHH6GsIawAQEugROqaQAkhGJ-h50a50W5oK62plvIkh7ju8nD_iPs71ZsCvrl_hlXuKU1x1wWDvCv3ivGux7XyzrXXvuvYHtq7VNdaxG4IJ2PquGWvg2c_l4m6BvXlyoffDKTq0ug7mbD-eoIdfi_v5Mrm--X01n10nJWdAksxqQalhhhSlECnl1lbAqwIk10IIWeacV7og8Y1S0xxynlUECpYXMjWykOwEfd_V3fjueWtCrxoXSlPXujXdNigZy4s0i1_1T5KxNJdEkEhmO7L0XQjeWLXxrtF-UATUaEat1ShAjQLUaEb9NaPeYuq3_SHbojHVR-K7igic7wEdSl1bH7W48MkxgJzwPHKXO-7V1Wb47wuo2e39GLE_chCohg</recordid><startdate>201008</startdate><enddate>201008</enddate><creator>Alam, I.</creator><creator>Stainbrook, T.</creator><creator>Cecil, B.</creator><creator>Kistler, K. D.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201008</creationdate><title>Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry</title><author>Alam, I. ; Stainbrook, T. ; Cecil, B. ; Kistler, K. D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4301-8fa622e3e1bc66524ffd04db074a6667c944dab10267a290948d10b39b75e7b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Data processing</topic><topic>Digestive system</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C virus</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medication Adherence</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Ribavirin</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - therapeutic use</topic><topic>Tablets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alam, I.</creatorcontrib><creatorcontrib>Stainbrook, T.</creatorcontrib><creatorcontrib>Cecil, B.</creatorcontrib><creatorcontrib>Kistler, K. D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alam, I.</au><au>Stainbrook, T.</au><au>Cecil, B.</au><au>Kistler, K. D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2010-08</date><risdate>2010</risdate><volume>32</volume><issue>4</issue><spage>535</spage><epage>542</epage><pages>535-542</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Aliment Pharmacol Ther 2010; 32: 535–542
Summary
Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily.
Aim To examine whether improved adherence was associated with RBP vs. RBV.
Methods Accurate Dosing in Hepatitis C: Examining the RibaPak Experience (ADHERE) was a U.S., multi‐centre, prospective registry capturing data on adherence with RBP vs. RBV in adults with HCV. Adherence was measured by the proportion of subjects remaining on treatment at weeks 4, 12 and 24; by pill counts; and by the proportion of subjects who took ≥80% of their prescribed dose.
Results A total of 503 patients (RBP = 346, RBV = 157) from 33 sites were included. A greater proportion of RBV vs. RBP subjects prematurely discontinued treatment. At 12 and 24 weeks, a greater proportion of RBP vs. RBV subjects took ≥80% of their prescribed doses (P < 0.05). For patients who remained on treatment, the mean milligrams missed per day was significantly greater for RBV vs. RBP at 24 weeks.
Conclusions First line treatment with RBP may offer the best prospect for less discontinuation and improved treatment adherence.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20500732</pmid><doi>10.1111/j.1365-2036.2010.04381.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2010-08, Vol.32 (4), p.535-542 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_762265820 |
| source | MEDLINE; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Administration, Oral Adult Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Biological and medical sciences Data processing Digestive system Female Gastroenterology. Liver. Pancreas. Abdomen Hepatitis C Hepatitis C - drug therapy Hepatitis C virus Humans Male Medical sciences Medication Adherence Middle Aged Pharmacology. Drug treatments Prospective Studies Registries Ribavirin Ribavirin - administration & dosage Ribavirin - therapeutic use Tablets |
| title | Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T07%3A39%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20adherence%20to%20HCV%20therapy%20with%20higher%20dose%20ribavirin%20formulation:%20final%20analyses%20from%20the%20ADHERE%20registry&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Alam,%20I.&rft.date=2010-08&rft.volume=32&rft.issue=4&rft.spage=535&rft.epage=542&rft.pages=535-542&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2010.04381.x&rft_dat=%3Cproquest_cross%3E733597161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733597161&rft_id=info:pmid/20500732&rfr_iscdi=true |